Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (287K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Carbone, G. M.
Right arrow Articles by Catapano, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carbone, G. M.
Right arrow Articles by Catapano, C. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2003, Vol. 31, No. 3 833-843
© 2003 Oxford University Press

Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide

Giuseppina M. Carbone*,1,2, Eileen M. McGuffie1,3, Angela Collier1,3 and Carlo V. Catapano1,3

1 Laboratory of Cancer Genomics, Hollings Cancer Center, 2 Department of Pathology and Laboratory Medicine and 3 Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA

*To whom correspondence should be addressed. Tel: +1 843 792 2128; Fax: +1 843 792 3200; Email: carbonep{at}musc.edu

The transcription factor Ets2 has a role in cancer development and represents an attractive therapeutic target. In this study, we designed a triplex-forming oligonucleotide (TFO) directed to a homopurine:homopyrimidine sequence in the Ets2 promoter. Transcription factors of the Sp family bound to this sequence and mutation of the Sp1 site reduced Ets2 promoter activity. The Ets2-TFO had high binding affinity for the target sequence and inhibited binding of Sp1/Sp3 to the overlapping site. This effect occurred with a high degree of sequence specificity. Mismatched oligonucleotides did not inhibit Sp1/Sp3 binding and mutations in the target sequence that abolished triplex formation prevented inhibition of Sp1/Sp3 binding by the TFO. The Ets2-TFO inhibited Ets2 promoter activity and expression of the endogenous gene in prostate cancer cells at nanomolar concentrations. The TFO did not affect reporter constructs with mutations in the TFO binding site and promoters of non-targeted genes. Expression of non-targeted genes was also not affected in TFO-treated cells. Collectively, these data demonstrated that the anti-transcriptional activity of the Ets2-TFO was sequence- and target-specific, and ruled out alternative, non-triplex mediated mechanisms of action. This anti-transcriptional approach may be useful to examine the effects of selective downregulation of Ets2 expression and may have therapeutic applications.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
M. Duca, P. Vekhoff, K. Oussedik, L. Halby, and P. B. Arimondo
The triple helix: 50 years later, the outcome
Nucleic Acids Res., September 1, 2008; 36(16): 5123 - 5138.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
M. Paramasivam, S. Cogoi, V. V. Filichev, N. Bomholt, E. B. Pedersen, and L. E. Xodo
Purine twisted-intercalating nucleic acids: a new class of anti-gene molecules resistant to potassium-induced aggregation
Nucleic Acids Res., June 1, 2008; 36(10): 3494 - 3507.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
V. Albertini, A. Jain, S. Vignati, S. Napoli, A. Rinaldi, I. Kwee, M. Nur-e-Alam, J. Bergant, F. Bertoni, G. M. Carbone, et al.
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.
Nucleic Acids Res., January 1, 2006; 34(6): 1721 - 1734.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
R. Thenmalarchelvi and N. Yathindra
New insights into DNA triplexes: residual twist and radial difference as measures of base triplet non-isomorphism and their implication to sequence-dependent non-uniform DNA triplex.
Nucleic Acids Res., January 1, 2005; 33(1): 43 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
G. M. Carbone, S. Napoli, A. Valentini, F. Cavalli, D. K. Watson, and C. V. Catapano
Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells
Nucleic Acids Res., August 16, 2004; 32(14): 4358 - 4367.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
G. M. Carbone, E. McGuffie, S. Napoli, C. E. Flanagan, C. Dembech, U. Negri, F. Arcamone, M. L. Capobianco, and C. V. Catapano
DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene
Nucleic Acids Res., April 30, 2004; 32(8): 2396 - 2410.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T. G. Uil, H. J. Haisma, and M. G. Rots
Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities
Nucleic Acids Res., November 1, 2003; 31(21): 6064 - 6078.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
R. A. Cassidy, N. Puri, and P. S. Miller
Effect of DNA target sequence on triplex formation by oligo-2'-deoxy- and 2'-O-methylribonucleotides
Nucleic Acids Res., July 15, 2003; 31(14): 4099 - 4108.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.